Literature DB >> 23485097

The prognostic value of HRCT in myositis-associated interstitial lung disease.

Kiminobu Tanizawa1, Tomohiro Handa, Ran Nakashima, Takeshi Kubo, Yuji Hosono, Kensaku Aihara, Kohei Ikezoe, Kizuku Watanabe, Yoshio Taguchi, Kazuhiro Hatta, Toru Oga, Kazuo Chin, Sonoko Nagai, Tsuneyo Mimori, Michiaki Mishima.   

Abstract

BACKGROUND: Polymyositis and dermatomyositis-associated interstitial lung disease (PM/DM-ILD) can have variable courses. We evaluated the prognostic value of high-resolution computed tomography (HRCT) in PM/DM-ILD.
METHODS: The cases of 51 patients newly diagnosed with PM/DM-ILD were retrospectively reviewed. HRCT images at diagnosis were categorized into four radiological patterns based on the major findings and distributions of these abnormalities, and the disease extent on HRCT was scored. The impact of HRCT findings and other clinical parameters on day 90 and overall mortality were analyzed.
RESULTS: Of the 51 patients (11 with polymyositis and 40 with dermatomyositis), the lower consolidation/ground-glass attenuation (GGA) pattern was observed in 21 patients (41%), lower reticulation was observed in 23 patients (45%), random GGA was observed in four patients (8%), and other patterns were observed in three patients (6%). Twenty-one patients (42%) were positive for anti-CADM-140. The lower consolidation/GGA pattern, clinically amyopathic dermatomyositis, fever (≥38.0 °C), ferritin levels >500 ng/mL, and the presence of anti-CADM-140 were significantly associated with 90-day mortality in univariate analysis. Multivariate analysis revealed that the lower consolidation/GGA pattern (odds ratio, 23.1; P = 0.02) and the presence of anti-CADM-140 (odds ratio, 14.1; P = 0.03) were independent predictors of 90-day mortality. This HRCT pattern was also associated with a higher 90-day morality rate among anti-CADM-140-positive patients. The lower consolidation/GGA pattern was also associated with overall mortality in univariate analysis, whereas only the presence of anti-CADM-140 was an independent determinant of overall mortality in multivariate analysis.
CONCLUSION: HRCT patterns at diagnosis can help predict the prognosis of patients with PM/DM-ILD as well as the presence of anti-CADM-140.
Copyright © 2013 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23485097     DOI: 10.1016/j.rmed.2013.01.014

Source DB:  PubMed          Journal:  Respir Med        ISSN: 0954-6111            Impact factor:   3.415


  22 in total

Review 1.  Management of interstitial lung disease associated with connective tissue disease.

Authors:  Stephen C Mathai; Sonye K Danoff
Journal:  BMJ       Date:  2016-02-24

2.  HRCT score and serum ferritin level are factors associated to the 1-year mortality of acute interstitial lung disease in clinically amyopathic dermatomyositis patients.

Authors:  Jing Zou; Qiang Guo; Jiachang Chi; Huawei Wu; Chunde Bao
Journal:  Clin Rheumatol       Date:  2015-01-23       Impact factor: 2.980

3.  Idiopathic inflammatory myopathies: CT characteristics of interstitial lung disease and their association(s) with myositis-specific autoantibodies.

Authors:  Amandine Laporte; Kubéraka Mariampillai; Yves Allenbach; Nicoletta Pasi; Victoria Donciu; Dan Toledano; Benjamin Granger; Olivier Benveniste; Philippe A Grenier; Samia Boussouar
Journal:  Eur Radiol       Date:  2022-01-13       Impact factor: 5.315

4.  18F-FDG PET/CT and HRCT: a combined tool for risk stratification in idiopathic inflammatory myopathy-associated interstitial lung disease.

Authors:  Yuying Zhang; Zhifeng Chen; Yali Long; Bing Zhang; Qiao He; Kejing Tang; Xiangsong Zhang
Journal:  Clin Rheumatol       Date:  2022-06-27       Impact factor: 3.650

5.  Prognostic factors in a cohort of antisynthetase syndrome (ASS): serologic profile is associated with mortality in patients with interstitial lung disease (ILD).

Authors:  Jorge Rojas-Serrano; Denisse Herrera-Bringas; Mayra Mejía; Hermes Rivero; Heidegger Mateos-Toledo; José E Figueroa
Journal:  Clin Rheumatol       Date:  2015-07-30       Impact factor: 2.980

Review 6.  Idiopathic inflammatory myopathies.

Authors:  Mazen M Dimachkie; Richard J Barohn; Anthony A Amato
Journal:  Neurol Clin       Date:  2014-08       Impact factor: 3.806

7.  Prognostic significance of anti-aminoacyl-tRNA synthetase antibodies in polymyositis/dermatomyositis-associated interstitial lung disease: a retrospective case control study.

Authors:  Hironao Hozumi; Noriyuki Enomoto; Masato Kono; Tomoyuki Fujisawa; Naoki Inui; Yutaro Nakamura; Hiromitsu Sumikawa; Takeshi Johkoh; Ran Nakashima; Yoshitaka Imura; Tsuneyo Mimori; Takafumi Suda
Journal:  PLoS One       Date:  2015-03-19       Impact factor: 3.240

8.  Prognostic factors for myositis-associated interstitial lung disease.

Authors:  Tomoyuki Fujisawa; Hironao Hozumi; Masato Kono; Noriyuki Enomoto; Dai Hashimoto; Yutaro Nakamura; Naoki Inui; Koshi Yokomura; Naoki Koshimizu; Mikio Toyoshima; Toshihiro Shirai; Kazumasa Yasuda; Hiroshi Hayakawa; Takafumi Suda
Journal:  PLoS One       Date:  2014-06-06       Impact factor: 3.240

Review 9.  Factors Associated with Interstitial Lung Disease in Patients with Polymyositis and Dermatomyositis: A Systematic Review and Meta-Analysis.

Authors:  Li Zhang; Guoqin Wu; Di Gao; Guijian Liu; Lin Pan; Liyan Ni; Zheng Li; Qiang Wang
Journal:  PLoS One       Date:  2016-05-12       Impact factor: 3.240

10.  HMGB1 May Be a Biomarker for Predicting the Outcome in Patients with Polymyositis /Dermatomyositis with Interstitial Lung Disease.

Authors:  Xiaoming Shu; Qinglin Peng; Xin Lu; Guochun Wang
Journal:  PLoS One       Date:  2016-08-18       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.